AIM ImmunoTech Inc. — Q2 2022 Form 10-Q
Reporting period: Three and six months ended June 30, 2022. Dollar amounts below are in millions unless stated otherwise. AIM is a clinical-stage immunopharmaceutical company focused primarily on Ampligen; the product is not FDA-approved or marketed in the United States.
Financial performance and liquidity
| Metric | Q2 2022 | Q2 2021 | Six months 2022 | Six months 2021 |
|---|---|---|---|---|
| Revenue | $0.030 | $0.023 | $0.064 | $0.052 |
| Operating loss | $(4.695) | $(3.718) | $(7.847) | $(7.463) |
| Net loss | $(4.851) | $(5.876) | $(8.671) | $(9.455) |
| Loss per share | $(0.10) | $(0.12) | $(0.18) | $(0.20) |
| Research and development expense | $2.475 | $1.317 | $3.511 | $2.742 |
| General and administrative expense | $2.181 | $2.145 | $4.253 | $4.256 |
- Revenue came from the Ampligen cost-recovery program, not material commercial sales. The filing does not provide a meaningful operating margin; revenue remains very small relative to expenses.
- Six-month operating cash use was $5.071 million, versus $4.763 million in 2021. Investing activities provided $7.375 million, primarily reflecting net marketable-security sales; financing activities provided $0.055 million. Cash and equivalents increased by $2.359 million to $34.452 million.
- At June 30, cash, equivalents and marketable securities totaled $41.772 million, down from $48.268 million at December 31, 2021. Total current assets were $46.045 million and current liabilities $1.368 million. Total assets were $50.884 million; stockholders’ equity was $48.780 million.
- The company reported no debt at quarter-end. Operating lease liabilities totaled $0.889 million; redeemable warrants were valued at approximately $0.001 million.
Changes versus the prior-year period
- Six-month net loss narrowed by $0.784 million, despite higher R&D costs and a $1.404 million investment loss. Lower production costs and the absence of the prior-year $2.701 million debt-extinguishment expense helped the comparison.
- Q2 net loss narrowed by $1.025 million, mainly because the prior-year quarter included a $2.701 million debt-extinguishment expense. Q2 R&D expense increased $1.158 million, largely due to clinical-trial spending, including Amarex.
- Marketable securities declined to $7.320 million from $16.175 million at year-end; the company recorded a $1.404 million six-month investment loss.
Outlook, developments and risks
- Management said existing resources were expected to fund anticipated operations and current clinical trials for approximately 24 months. AIM reported no material operating revenue and expects none in the near term; additional financing may be needed. A new shelf registration statement became effective in February 2022, but future financing could dilute shareholders.
- AIM’s planned Phase 2 pancreatic-cancer trial, AMP-270, was cleared to proceed after an FDA clinical hold was lifted. The company anticipates a cost of approximately $8.2 million and a duration of about 4.6 years; the planned study is expected to enroll about 90 patients.
- A planned Phase 2 Post-COVID conditions trial is subject to FDA authorization. AIM estimated a cost of approximately $4.4 million, excluding certain third-party costs and escalations.
- The New Brunswick manufacturing property was classified as held for sale at $3.9 million. The sale closing was extended to August 31, 2022, subject to further extension rights. AIM also entered a lease for a new New Jersey R&D facility, commencing July 2022.
- Alferon production was on hold, with no definitive restart timetable; renewed commercial sales depend on manufacturing arrangements and FDA approvals. Ampligen’s Argentina launch also remained pending final inspection and product-release steps.
- After quarter-end, AIM disclosed competing lawsuits related to an activist shareholder’s attempted director nominations and board-control dispute. The company warned that litigation and a proxy contest could divert management, increase costs and affect operations or stock price.
- AIM terminated its Smoore agreement on August 10, 2022, citing delays and obstacles importing Ampligen to China. The company emphasized that clinical outcomes, regulatory approvals, manufacturing capacity and future funding remain uncertain.
Investor verification priorities
- Track actual cash burn, investment values and the timing of any additional capital raise against management’s approximately 24-month runway estimate.
- Verify AMP-270 trial initiation, enrollment, total costs and funding, and whether FDA authorization is obtained for the Post-COVID trial.
- Confirm completion and proceeds of the $3.9 million property sale, and assess the costs and operational implications of the new facility lease.
- Monitor regulatory and manufacturing milestones for Ampligen and Alferon, including Argentina’s pending launch requirements and Alferon’s production restart.
- Follow the activist litigation and any resulting board or strategic changes; evaluate reported clinical findings in light of study size, design and whether they are independently confirmed.